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Purpose:Whereas T2 hyperintensities known as NF-associated bright spots are well described in patients with
neuroﬁbromatosis type I (NF-1), there is a paucity of data on incidental ﬁndings in patients with neuroﬁbroma-
tosis type II (NF-2). We aim to characterize unexplained imaging ﬁndings in the brains of patients with NF-2.
Materials and methods: This study is retrospective, HIPAA-compliant and approved by the institutional review
board. 34 patients with NF-2 underwent brain magnetic resonance imaging (MRI) between January 2000 and
December 2012. T2 and T1-weighted imaging characteristics, diffusion weighted imaging (DWI) characteristics,
and enhancement patternswere analyzed by visual inspection. Clinical information at time of imagingwas avail-
able for all patients. Neuropathologic data was available for one patient.
Results:We found unexplained T2 hyperintensities present on initial imaging in 23/34 patients (67%). Of the 23
patientswith unexplainedMRIﬁndings, 15 (65%) hadwedge-shaped T2hyperintensities in the subcorticalwhite
matter extending to the cortex suggestive of a cortical dysplasia. 3 additional cases (17%) had a lesion within the
cerebellum suggestive of a neuronal migration anomaly. In one patient where the MRI was suggestive of focal
cortical dysplasia, histopathologic analysis revealed dysplastic glial fociwithout other alterations of cortical archi-
tecture or other cytologic abnormalities.
Conclusion: Unexplained T2 hyperintensities occur frequently in patients with NF-2. While they may not be the
NF-2 equivalent of NF-associated bright spots seen in NF-1, some of these T2 hyperintensities in patients with
NF-2 may represent underlying disorders of neuronal migration. Further studies are needed to validate our
ﬁndings.© 2014 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Neuroﬁbromatosis type II (NF-2) is a neurocutaneous disorder that
is caused by genetic mutations of the NF-2 gene on chromosome 22
(Rouleau et al., 1993). The NF-2 gene encodes an intracellular
membrane-associated protein, a tumor suppressor known as merlin
(Trofatter et al., 1993). Aberrant merlin predisposes individuals with
NF-2 to the development of multiple tumors of the central nervous sys-
tem, including meningiomas, schwannomas and ependymomas
(Asthagiri et al., 2009;Hagel et al., 2012). Themost commonof these tu-
mors are bilateral vestibular schwannomas. Spinal cord tumors are also
a prominent component of NF-2.erms of the Creative Commons
icense, which permits non-
dium, provided the original au-
oor, New York, NY 10021, USA.
lished by Elsevier Inc. All rights reserHyperintensities on T2-weighted images known as NF-associated
bright spots are seen in the brain MRIs of most patients with the other
type of neuroﬁbromatosis, neuroﬁbromatosis type I (NF-1) (van
Engelen et al., 2008). NF-associated bright spots are focal areas of in-
creased signal intensity that occur most often in the basal ganglia, cere-
bellum, brainstem, and subcortical white matter. Pathologic studies
performed in NF-1 so far have revealed intramyelinic vacuolar changes
or spongiotic myelinopathy that correlate with the hyperintensities
found on T2-weighted images (DiPaolo et al., 1995). However, there is
a lack of data on the existence and signiﬁcance of unexplained imaging
ﬁndings in the brains of patients with NF-2. One case report suggests
that hyperintensities seen on T2-weighted imaging in the brain of a
21-year-old man with NF-2 were likely due to myelin vacuolization
(Sener et al., 2003). This assumption was based primarily on MRI ap-
pearance as there was no corresponding histopathology. Furthermore,
there are no large-scale pathologic studies on these hyperintensities
seen on T2-weighted images in the brains of patients with NF-2.
The purpose of this study was to characterize unexplained T2-
hyperintense lesions and other incidental brainMRI ﬁndings in patients
with NF-2 in an effort to elucidate speciﬁc patterns.ved.
Table 2
Results.
Incidental brain MRI ﬁnding Number of patients
with ﬁnding, no. (%)
Any incidental ﬁnding 23 (68)
Nonspeciﬁc T2 hyperintensities 17 (74)
Wedge shaped cortical/subcortical T2 hyperintense 15 (65)
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Our retrospective study was approved by our institutional review
board, and informed consent was waived. Our study was compliant
with the Health Insurance Portability and Accountability Act.
2.1. Study design and patients
We performed a retrospective analysis of brain imaging, histopa-
thology and clinical data on patients with NF-2 to characterize unex-
plained brain lesions in this population. Patients were included in this
study if they had a deﬁnitive clinical and/or genetic diagnosis of NF-2
and had brain MRI imaging performed consecutively anytime between
January 2000 and December 2012. The lesion inclusion criteria were le-
sions present on available initial brain MRI and lesions not otherwise
explained by tumor, edema, radiation changes or postoperative chang-
es. Brain MRI scans obtained without gadolinium were excluded from
the study. Patients who had only one brain MRI available for review
were also excluded from the study. Of 37 patients with NF-2 and avail-
able imaging during this time period, 34 had two or more brain MRI
scans performed. The remaining 3 patients only had spinal imaging
available and were excluded from the study. Neuropathologic data
was available for one patient who expired during this time period and
had complete autopsy performed.
2.2. Image acquisition
All patients were examined with a 1.5-T whole-body MR imaging
unit (Echospeed; GEMedical Systems, Milwaukee,Wisconsin) equipped
with high-performance gradients and a manufacturer-supplied quadra-
ture head coil. The following conventional sequences were performed:
sagittal T1-weighted (300/14 [repetition time in ms/echo time in ms],
one signal acquired), transverse T2-weighted fast spin-echo (3000/91,
one signal acquired), transverse fast ﬂuid-attenuated inversion-
recovery (10,002/172, inversion time of 2.2 s, one signal acquired),
transverse T1-weighted (500/14, one signal acquired), and transverse
diffusion-weighted echo-planar (6000/99–100, one signal acquired, b
values of 0 and 1000 s/mm2) MR imaging. The transverse sequences
usually involved the use of a 5-mm section thickness with an intersec-
tion gap of 2.5 mm, a 256 × 192 matrix, the same imaging angle along
the orbitomeatal line, and a 22- or 24-cm ﬁeld of view. Gadopentetate
dimeglumine (Multi-Hance; Bracco Diagnostics, Princeton, NJ) was ad-
ministeredwith eachMRI scan to allow for the evaluation of contrast en-
hancement. Contrast agent administrationwas performed intravenously
in an identical manner with a power injector at a rate of 2 mL/s with a
20-gauge needle unless patient-related factors (e.g., small veins) neces-
sitated the use of a needle with a different size.
2.3. Data interpretation
All images were independently analyzed by visual inspection by an
experienced pediatric neuroradiologist (L.A.H.) with 30 years of experi-
ence interpreting brain MRI to exclude tumors, vasogenic edema or
post-operative changes within the central nervous system (CNS) and
to characterize the ﬁndings. In addition to T2-weighted imaging charac-
teristics, T1-weighted imaging characteristics, diffusionweighted imag-
ing (DWI) characteristics, and enhancement patterns were analyzed to
characterize associated abnormalities. Clinical data at time of allTable 1
Patient demographics.
Number of patients in the study (N) 34
Median age at time of ﬁrst incidental MRI ﬁnding (years) 20
Female, no. (%) 11 (32)
Male, no. (%) 23 (68)
Received cranial irradiation, no. (%) 3 (9)imaging was available for all patients. Spearman's correlation between
patient age and number of unexplained lesions was calculated. The his-
topathologic data was independently analyzed by an experienced neu-
ropathologist (F.R.) with 11 years of experience in interpreting both
neoplastic and nonneoplastic neuropathology.
3. Results
A total of 34 patients were included in this study. 23/34 (68%) were
males and 11/34 (32%) were females. The median age at time of unex-
plained brain MRI ﬁnding was 20 years old (range 8–69 years)
(Table 1). 23/34 patients (68%) had at least one unexplained ﬁnding
present on the initial MRI of the brain (Table 2). A total of 73 incidental
lesionswere identiﬁed among the 23 initial patientMRIs. 22/23 patients
(96%) had at least one incidental hyperintense ﬁnding on T2-weighted
imaging. The remaining patient with unexplained abnormal imaging
had a purely cortical T1 hypointense and T2 hypointense lesion. The av-
erage number of unexplained T2-hyperintensities for all study patients
at time of initial brain imaging was 2.2 ± 2.3. The most common loca-
tion for these T2-hyperintense lesions was the frontal lobe, with a
higher frequency appearing in the right frontal lobe. During consecutive
brain imaging over a period of at least six months (range up to
12 years), no patient (0%) developed any new unexplained lesions
and only two patients were noted to have an increase in incidental le-
sion size. One patient developed interval increase in the size of his unex-
plained T2-hyperintense lesion; this patient was among three patients
in our study who had received brain radiation. One patient developed
an increase in size of a cortical T2 hypointensity (Fig. 1). The remainder
of the cases (94%) had no interval change in the size of any of their un-
explained lesions. Of the three patients with a history of cranial irradia-
tion, one did not have any unexplained abnormalities on initial or
subsequent brain MRI. The other two had incidental ﬁndings present
on brain MRI prior to the initiation of radiation therapy. The patient
with a change in his lesions received conformal radiation therapy with
a total of 5400 cGy to the right parietal area for ependymoma complet-
ed in December 2007. His unexplained lesions were ﬁrst noted prior to
radiation treatment in May 2007. He developed diffuse white matter
T2-hyperintensities in December 2009. A second patient received con-
formal radiation (dose unknown as performed at an outside institution)
to the lower brain stem/upper cervical cord for neuroﬁbroma complet-
ed in 1991. His unexplained lesion was ﬁrst noted inMay 2007 andwas
not observed to change over time. A third patient received conformal ra-
diation (dose unknown as performed at an outside institution) to the
right orbit and right skull base for spheno-orbital meningioma complet-
ed in April 2004. His unexplained lesions were ﬁrst noted prior to radi-
ation therapy in May 2002 and were not noted to change over time.
Among all 73 incidental lesions, only one was hyperintense on T1-
weighted sequences. A total of three unexplained gadolinium-
enhancing lesions were identiﬁed (4%). Among the three enhancing le-
sions was leptomeningeal enhancement over a wedge-shaped corticallesions
Transmantle sign 9 (39)
Cortical T2 hypointensities 8 (34)
Well circumscribed cortical T2 hypointensity with
associated T1 hypointensity
6 (26)
Migrational cerebellar anomalies 3 (13)
T2 hyperintense lesions associated with an enlarged
Virchow–Robin space
7 (30)
More than one of the above abnormalities 15 (65)
a) 2004 b) 2010
Fig. 1. Cortical T2-hypointense lesion seen on MRI imaging of a 13-year-old boy with NF-2. Transverse fast ﬂuid-attenuated inversion-recovery (FLAIR) images in a boy with NF-2 dem-
onstrate a cortical hypointense lesion in the right anterior temporal lobe (orange arrows) present on initial imaging in 2004 (a) that grew in size when imaged 6 years later (b).
260 W.S. Vargas et al. / NeuroImage: Clinical 4 (2014) 258–265right anterior temporal lesion (Fig. 2). Seven of the 23 patients (30%)
had T2 hyperintense lesions associated with an enlarged Virchow–
Robin space (Fig. 3). Nine of 23 patients (39%) had hyperintense cone-
shaped lesions with subcortical extension thinning towards the lateral
ventricles (the classic so called “transmantle sign”) on T2 and ﬂuid-
attenuated inverse recovery (FLAIR) sequences (Fig. 4; Table 3). An ad-
ditional six of 23 (26%) patients hadwedge-shaped cortical and subcor-
tical T2 hyperintense lesions without the classic transmantle sign but
suggestive of cortical dysplasia nonetheless (Fig. 5; Table 3). Six of the
23 (26%) patients hadwell circumscribed lesions thatwere hypointense
on T1 and T2-weighted sequences suggestive of mineralization (Fig. 6).
In addition, three patients (13%) had a lesionwithin the cerebellum sus-
picious for a disorder of neuronal migration (Fig. 7). Two of these 3 pa-
tients (67%) displayed the classic “transmantle sign” in the right
cerebellum. The remaining patient had a cleft within the left cerebellumFig. 2. Leptomeningeal enhancement associatedwith a cortical T2-hyperintensewedge shaped l
shaped hypointense lesion situated in the right anterior temporal cortex (arrow). (b) Transver
and demonstrates mild mass effect with erosion of the inner skull table. (c) Transverse T1-wei
the wedge-shaped right temporal cortical lesion.lined with cortical gray matter. None of the patients (0%) had epilepsy
or a documented cognitive deﬁcit. Overall we found that younger age
at diagnosis of NF-2 correlated inversely with number of incidental le-
sions found on the initial brain MRI (Fig. 8).
Microscopic examination of the deep gray matter of one patient in
whom there was a “transmantle sign” on brain MRI suggestive of corti-
cal dysplasia revealed micro-hamartomas without the classic histologic
features of cortex dysplasia (Fig. 9).
4. Discussion
In our study, we characterized unexplained T2 hyperintensities and
other incidental ﬁndings seen in the brains of patients with NF-2. Our
data suggest that in some patients with NF-2 and unexplained T2
hyperintensities, these lesions may represent an underlying disorderesion in a 13-year-old boywithNF-2. (a) Transverse T1-weighted sequence shows awedge
se T2-weighted fast spin-echo sequence shows that the lesion is T2-hyperintense (arrow)
ghted post-gadolinium sequence reveals mild leptomeningeal enhancement (arrow) over
Fig. 3. Periventricular T2-hyperintense lesion associated with enlarged Virchow–Robin space in a 20-year-old man with NF-2. (a) Transverse fast ﬂuid-attenuated inversion-recovery
(FLAIR) sequence shows left periventricular hyperintensity surrounding a dilated Virchow–Robin space (arrow). (b) Transverse T2-weighted fast spin-echo sequence shows that the le-
sion is T2-hyperintense (arrow). Transverse T1-weighted sequence pre-gadolinium (c) and post-gadolinium (d) administration reveal that the lesion does not contrast-enhance.
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humans with NF-2, though it has been previously reported (Ruggieri
et al., 2005; Ruggieri et al., 2013; Wiestler et al., 1989). Interestingly
though, animal studies have suggested that merlin may play a role in
neuronalmigration (Huynh et al., 1996). Huynh et al. (1996) sequenced
the NF-2 gene in mice embryos and used in situ hybridization and anti-
merlin antibodies to determine the developmental expression of the
NF-2 gene. They found that in cells migrating from the ventricular
zone to the cortical plate on embryonic days 15 and 16,merlinwas pres-
ent only in the cells of the intermediate zone and absent at both the ven-
tricular zone and the cortical plate. The authors suggest that the tightly
regulated expression of merlin during migration of cells to the cortical
plate might predict cortical abnormalities in patients with NF-2 gene
mutations (Huynh et al., 1996). A history of seizures has been reported
in 4 to 24% of patients with NF-2 (Evans et al., 1999; Ruggieri et al.,
2005), and it is tempting to attribute this epileptic tendency to cortical
dysplasia. In our cohort, we did not ﬁnd an associated tendency towards
seizures or learning disabilities in individuals with imaging characteris-
tics of cortex dysplasia, but this lack of correlation may reﬂect our small
sample size.a b
Fig. 4. Possible transmantle sign in a 20-year-old man with NF-2. (a) Transverse fast ﬂuid-atten
sion (arrow) extending towards the ventricle in a 20-year-old man with NF-2, suggestive of th
lesion is T2-hyperintense (arrow). (c) Post-gadolinium transverse T1-weighted sequence failsMerlin is a cytoskeleton membrane scaffolding protein, and many
protein factors are known to interact with merlin. Protection offered
by the regulatory mechanisms associated with these protein factors
may offer a possible mechanism for the lack of seizures in our patients
with NF-2 and radiographic evidence of a FCD. Histopathologic differ-
ences between true focal cortical dysplasias and the cortical lesions
we have observed in the brains of patients with NF-2 provide another
possible explanation. Furthermore, cases of cortical dysplasia without
seizures andwith normal neurodevelopmental outcomes have been re-
ported (Packard et al., 1997).
The focal cortical dysplasias (FCDs) can be classiﬁed into three major
categories based on histopathologic ﬁndings (Blumcke et al., 2011).
When a focal cortical dysplasia is either clinically or radiologically
suspected but the lesion is not available for microscopic inspection, this
is termed FCD Type III not otherwise speciﬁed (FCD Type III NOS). There-
fore, almost all of our subcategory of patients with radiographic ﬁndings
suspicious for FCD could be classiﬁed as FCD Type III NOS under themost
recent classiﬁcation system for focal cortical dysplasias (Bailey and
Hermann, 1938). One patient for whom neuropathology was available
was noted to have foci of dysplastic, immature neuroectodermal cellsc
uated inversion-recovery (FLAIR) image reveals a wedge-shaped cortical hyperintense le-
e “transmantle sign”. (b) Transverse T2-weighted fast spin-echo sequence shows that the
to show contrast-enhancement.
Table 3
Characteristics of those patients found to have MRI suspicious for cortical/cerebellar dys-
plasias.
Number of cases 16
Female 5 (31%)
Male 11 (69%)
Median age at MRI ﬁnding of cortical dysplasia (years) 19.5
Finding present on initial available brain MRI 16 (100%)
Change over time (# pts) 2 (1%)
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hamartomas. Glial micro-hamartomas are common in NF-2, being
found in at least all cases in one series and correspond to dysplastic foci
of immature neuroectodermal cells in the cerebral cortex of these pa-
tients (Wiestler et al., 1989). These cells have been found at autopsy in
the cerebral cortex and basal ganglia of patients with NF-2 (Wiestler
et al., 1989; Bailey and Hermann, 1938; Orzechowski and Nowicki,
1912; Rubenstein, 1963; Rubenstein, 1986). These cells, although often
polymorphic andmultinuclear, have not shownmitotic activity or a ten-
dency for neoplastic transformation (Wiestler et al., 1989). While our
patient's MRI showed the classic “transmantle sign”, his histopathologic
ﬁndings were not in keeping with FCDs that are typically associated
with the “transmantle sign”. The “transmantle sign” refers to white
matter signal alterations that taper from the crown of a gyrus or bottom
of a sulcus towards the ventricle, reﬂecting the involvement of radial
glialneuronal units. This “transmantle sign”,ﬁrst describedbyBarkovich
in 1997, is almost exclusively found in FCD Type IIb (Barkovich et al.,
1997). Under the new FCD classiﬁcation, FCD Type IIb is an isolated le-
sion characterized by cortical dyslamination and dysmorphic neurons
with balloon cells (Blumcke et al., 2011). Balloon cells present with a
large cell body and opalescent glassy eosinophilic cytoplasm (using
H&E stain), which lacks Nissl substance. Our patient did not have any
evidence of cytologic abnormalities or cortical architecture despite hav-
ing the classicMRI ﬁnding, conﬁrming thewell accepted notion that the
neuroimaging characteristics of the FCDs are neither consistent nor re-
liable (Blumcke et al., 2011). Among the reported MRI ﬁndings of FCDs
are increased cortical thickness, blurring of the cortical-white matterFig. 5. Cortical T2-hyperintense lesion suggestive of cortical dysplasia in a 19-year-old woman
transverse T2-weighted fast spin-echo sequence (b) demonstrate a hyperintense lesion in the
pre-gadolinium (c) and post-gadolinium (d) administration reveal that the lesion does not conjunction, increased signal on T2 weighted images, a radially-oriented
linear or conical transmantle stripe of T2 hyperintensity, cortical thin-
ning, and localized brain atrophy (Blumcke et al., 2011). In keeping
with previous descriptions of patients with NF-2 and radiographic evi-
dence of FCD (Wiestler et al., 1989; Ruggieri et al., 2005; Ruggieri
et al., 2013), our patientswith radiographic evidence of cortex dysplasia
did not have seizures or cognitive dysfunction. This lack of clinical cor-
relation to what seemingly appears to be a focal cortical dysplasia on
MRI may be explained by the lack of cytologic abnormalities or cortical
architecture observed in one patient in this study with available
neuropathology.
It is interesting to note that six patients with lesions suspicious for
focal cortical dysplasias displayed a pattern of well circumscribed le-
sions with T1 and T2 hypointensity suggestive of mineralization. This
radiologic pattern has been described in patientswith focal cortical dys-
plasia type IIb (FCDIIb) with distinct allelic variants of the tuberous scle-
rosis complex 2 (TSC2) gene as identiﬁed by histopathologic genetic
sequencing (Schonberger et al., 2009). It should also be noted thatmer-
lin has been shown to interact with hamartin, one of the protein prod-
ucts of the gene mutation seen in tuberous sclerosis (Rosner et al.,
2008). The other diagnostic possibility for these 6 cases of well
circumscribed lesions with T1 and T2 hypointensity suggestive of min-
eralization is meningioangiomatosis. Some pathology-proven cases of
meningioangiomatosis look identical to our six cases (Izycka-
Swieszewska et al., 2000a), and the association of meningioangiomatosis
with NF-2 is well documented (Omeis et al., 2006).
The MRI pattern of mineralization within focal cortical dysplasias
is atypical for FCDIIb as it differs from the typical MRI characteristic
for FCDIIb of a funnel-shaped lesion tapering towards the lateral ven-
tricle on T2 and FLAIR sequences, the so-called “transmantle sign”
(Barkovich et al., 1997). Eight of our 15 patients (53%) with imaging
characteristics of disorders of neuronal migration did display this
classic “transmantle sign” suggestive of FCDIIb. It is interesting to
note that two out of three (67%) patients with cerebellar migrational
anomalies also displayed cortical migrational abnormalities.
We found a number of lesions which appeared to be T2 hyper-
intensities surrounding enlarged perivascular (Virchow–Robin) spaces.with NF-2. Transverse fast ﬂuid-attenuated inversion-recovery (FLAIR) sequence (a) and
right anterior frontal cortex which is wedge-shaped. Transverse T1-weighted sequence
trast-enhance.
Fig. 6. Purely cortical circular lesion in a 46-year-old man with NF-2. (a) Transverse fast ﬂuid-attenuated inversion-recovery (FLAIR) sequence shows a well-circumscribed hypointense
lesion in the left post-central gyrus (arrow). Transverse T1-weighted sequence pre-gadolinium(b) andpost-gadolinium(c) administration reveal that the lesion is T1-hypointense (b) and
does not enhance with contrast (c).
263W.S. Vargas et al. / NeuroImage: Clinical 4 (2014) 258–265Dilated perivascular spaces are a normal variant on MR imaging, and
they appear as well-deﬁned round or linear lesions, isointense to CSF
on all pulse sequences, and usually with no mass effect. Although the
exact mechanism for the development of enlarged perivascular spaces
remains unknown, mechanisms such as increased CSF pulsation, vascu-
lar ectasia or abnormality of arterial wall permeability may relate to
their formation. Unlike NF-1, vascular malformations such as arteriove-
nous ﬁstulas are not common in NF-2. Our ﬁndings of dilated Virchow–
Robin spaces in NF-2 however have been described in the NF-2 literature
(Fedi et al., 2009). Some authors have proposed that an obstructive
mechanism for CSF accumulation is the basis of the enlarged perivascular
spaces in NF-2 patients. Alternatively, it is possible that the enlarged
perivascular spaces and meningioangiomatosis are both the result of
an aberrant form of angiogenesis during development (Izycka-
Swieszewska et al., 2000b).Fig. 7. Transverse fast ﬂuid-attenuated inversion-recovery (FLAIR) sequences in a 13-year-old b
order of neuronal migration (arrows).In our study,we noted that younger age at timeof diagnosis correlat-
ed with greater number of incidental brain lesions. This ﬁnding may be
reﬂective of several processes. First, these children present at an earlier
age presumably because of more severe phenotype which may mirror
an aggressive overall radiological pattern. Alternatively, there may be
a pubertal inﬂuence on the development of these brain MRI anomalies.
Dermal neuroﬁbromas have been found to increase during puberty
(Duong et al., 2011) in patients with NF-1, and NF-related bright spots
show a progressive increase during adolescence (Kraut et al., 2004) in
NF-1. To our knowledge, the inﬂuence of puberty and other hormonal
factors in NF-2 has not been studied.
We did not observe the development of new incidental lesions over
time in our patients with baseline brain MRI abnormalities. In addition,
with the exception of one patient who had received radiation therapy,
the majority of patients in this study did not experience an increase inoy with NF-2 show a hyperintense lesion within the right cerebellum suspicious for a dis-
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Fig. 8. Scatterplot analysis of unexplained T2 hyperintensities as a function of age in 34 pa-
tients with NF-2. Younger age at diagnosis strongly correlated with higher number of in-
cidental lesions (Spearman's r = −0.56; p = 0.0006).
264 W.S. Vargas et al. / NeuroImage: Clinical 4 (2014) 258–265the size of T2 hyperintensities.While it is likely that radiation treatment
worsened the size of T2 hyperintensities in this one patient out of the
three total patients treatedwith radiation, overall we donot feel that ra-
diation was the inciting factor for the development of incidental lesions
in our cohort, as the majority of lesions were present prior to radiation
therapy. Given these ﬁndings of relative lesion stability over time, wec
a
Fig. 9.Micro-hamartomas in the brain of a 20-year-old man with NF-2. Low (a) and high (b)
radiographic evidence of cortex dysplasia reveal dysplastic foci of glial cells without alterati
inversion-recovery (FLAIR) sequences (c and d) demonstrate a cortical hyperintense lesion (arrfeel that brainMRI scanning outside of standard of care guidelines is un-
necessary in patients with NF-2. The clinical utility of our work lies in
the reassurance that can be given to patients and parents of children
with NF-2 much in the same manner that NF-related bright spots are
handled in NF-1. Our ﬁndings show that these incidental lesions in pa-
tients with NF-2 do not grow over time nor is there a change in other
imaging characteristics,whichwould be expected if these abnormalities
indeed represented neoplasms. This information is quite valuable given
that patients with NF-2 are inherently predisposed to the formation of
CNS neoplasms.
Our study had some limitations. First, the study was conducted in a
retrospective manner. The retrospective nature precluded exact MRI-
histopathologic correlation for the one study patient in whom autopsy
was performed. Second, the study may have been subject to selection
bias. Our centers are large, comprehensive neuroﬁbromatosis centers
and we see many patients with aggressive forms of NF-2. Third, we
did not use quantitative MRI measures such as DTI or MTR which can
probe the macromolecular and microstructural properties of brain tis-
sue and would have allowed for better imaging speciﬁcity. Most impor-
tantly, the histopathologic data was available for only one study patient
in whom the MRI was suggestive of a focal cortical dysplasia. Thus,
broad conclusions about the signiﬁcance of these MRI ﬁndings in pa-
tients with NF-2 cannot be drawn based on our study.
In conclusion, MRI ﬁndings suspicious for focal cortical dysplasias
occur commonly in patients with NF-2, and these imaging ﬁndings
may have histopathologic evidence of disruption of neuronal migration.
This disruption is unlikely to contain the classic cyto-architectural hall-
marks of true focal cortical dysplasia. Our study is the ﬁrst tod
b
quality magniﬁcation of an area of the left thalamic deep gray matter in this patient with
ons of cytologic abnormalities or cortical architecture. Transverse fast ﬂuid-attenuated
ows) suggestive of a cortical dysplasia in the left superior frontal gyrus in the same patient.
265W.S. Vargas et al. / NeuroImage: Clinical 4 (2014) 258–265characterize unexplained T2 hyperintensities and other incidental ﬁnd-
ings in patients with NF-2 and the ﬁrst to report MRI patterns typical of
focal cortical dysplasia with histopathologic evidence of dysplastic cor-
tical glial cells in a group of patients with neuroﬁbromatosis type II. Fur-
ther animal and histopathologic studies are needed to further delineate
the role of merlin in cortical migration and the frequency of MRI ﬁnd-
ings suspicious for focal cortical dysplasias in patients with NF-2.
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